Drugs / CD7 CAR-T
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05979792 | Sep 2023 → Aug 2025 | peripheral T-cell lymphoma, not otherwise specified | Zhao Weili | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04572308 | Oct 2020 → May 2021 | T lymphoblastic leukemia/lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07117305 | Sep 2025 → Sep 2027 expected | T-cell non-Hodgkin lymphoma | Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05909527 | May 2023 → Aug 2028 | T-cell acute lymphoblastic leukemia | Guangzhou Bio-gene Technology Co., Ltd | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07106723 | Jun 2025 → Jan 2029 expected | T-cell non-Hodgkin lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07008872 | Jun 2025 → May 2027 expected | acute leukemia, lymphoma | Qi deng | Not yet recruiting | No outcome recorded |
| — | NCT04938115 | May 2021 → May 2023 | T-cell leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Completed | No outcome recorded |
| — | NCT04785833 | Mar 2021 → Apr 2022 | T-cell acute lymphoblastic leukemia | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD7 CAR-T | “Clinical Study on the Efficacy and Safety of CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia” NCT07008872 ↗8“Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis” NCT04938115 ↗ “CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia” NCT04785833 ↗ “CD7 CAR-T Cell Injection” NCT05979792 ↗ |
| Known as | CD7-CAR T cells | “Allogeneic CD7-CAR T cells to bridge the gap?” PMID 36858787 ↗ Mar 2023 |
| Known as | dVHH NS7CAR-Ts | “In this phase 1 clinical trial, we evaluated the efficacy and safety of nanobody-based dVHH NS7CAR-Ts for patients with CD7+ refractory/relapsed AML.” PMID 39561281 ↗ Mar 2025 |
| Known as | NS7CAR-T | “This study included 24 patients (21 T-ALL, 3 T-LBL) who relapsed after first allo-HSCT and received naturally selected CD7 CAR-T (NS7CAR-T) therapy from patient-derived (n =...” PMID 42229585 ↗ Jun 2026 |
| Action | Deplete | “CAR-T therapy is to genetically modify the patient's T lymphocytes to target and eliminate tumor cells” NCT04785833 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T-cell (CAR-T) therapy” PMID 42229585 ↗ Jun 2026 |
| Route | Intravenous | “administered intravenously” NCT05909527 ↗ |
| Target | CD7 | “The CARs consist of an anti-CD7 single-chain variable fragment” NCT04572308 ↗ |